-
WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line
•
China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans to establish a new sterile filling line for prefilled syringes (PFS) at its facility in Leverkusen, Germany. This move is set to enhance the company’s drug product (DP) capabilities in the region, optimizing the facility’s…
-
Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance
•
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its JMX-2002 liposome injection. This innovative drug, known for its high efficiency and safety, is now set to commence clinical studies focusing on solid tumors, including non-small…
-
Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC
•
Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval from the National Medical Products Administration (NMPA) for its innovative therapy GZL-016. This approval marks a significant milestone in the development of mRNA T-cell receptor engineered T-cells (TCR-T) therapy aimed at treating hepatitis B virus-associated…
-
BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care
•
BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments, announced its intention to adopt a new English name: BeOne Medicines Ltd. The rebranding reflects the company’s mission to unite global efforts in the fight against cancer and underscores its transformative approach to fostering cross-sector…
-
Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
•
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from its Phase III SURMOUNT-1 study for tirzepatide, marking the longest completed study to date for the dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This data provides significant insights into the drug’s…
-
GE Healthcare’s SIGNA MAGNUS MRI Scanner Receives FDA 510(k) Clearance
•
US medical device and life sciences leader GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced the receipt of FDA 510(k) clearance for its innovative SIGNA MAGNUS, a 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This clearance marks a significant advancement in medical imaging technology, offering new capabilities for the…
-
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
•
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is poised to merge with US-based Pulmatrix, Inc. (NASDAQ: PULM). The merger will result in a Nasdaq-listed entity focused on advancing targeted protein degradation technology, a promising field in drug development. Cullgen’s uSMITE Technology PlatformCullgen leverages…
-
ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has announced the commencement of a Phase II clinical study for its investigational drug, IMM27M, targeting estrogen receptor positive (ER+) advanced breast cancer following endocrine therapy failure or recurrence. This announcement coincides with the enrollment of…
-
Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China
•
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with the issuance of the first national prescription for its biosimilar drug, SaiLeXin, at the Peking University People’s Hospital. This marks a new chapter in the treatment of autoimmune diseases in China, offering patients an alternative…
-
Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund
•
Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic investment totaling USD 20 million from global pharmaceutical leader Sanofi (NASDAQ: SNY) and Perceptive Xontogeny Venture Fund (PXV Fund I). This investment is a significant component of Zucara’s USD 20 million Series B financing round,…
-
Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment
•
The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted a marketing approval filing from Swiss pharmaceutical giant Novartis (NYSE: NVS) for its radioligand therapy (RLT), Pluvicto (177Lu vipivotide tetraxetan). This acceptance marks a significant step towards making this innovative treatment available to patients in…
-
Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC
•
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative oncology treatments, have jointly announced the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for their co-developed TROP-2-targeted antibody drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd). This application seeks…
-
Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed a strategic partnership with the Society for Neuroscience and Neurology, Chinese Research Hospital Association (SNN/CRHA). This collaboration is aimed at conducting comprehensive research into the genetic underpinnings of optic nerve-related diseases, marking a significant step…
-
BioNTech Seals Acquisition of China’s Biotheus for Up to $950M
•
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ: BNTX), marking a significant expansion of BioNTech’s operations in China. The deal underscores BioNTech’s commitment to enhancing its research and development capabilities and production capacity in the region. Deal Terms and FinancialsUnder the agreement, BioNTech…
-
Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China
•
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical (TYO: 4536) for the commercialization of ARVN001, an innovative triamcinolone acetonide suprachoroidal injectable suspension. This partnership marks a significant step in the expansion of ophthalmic treatments, with Santen securing exclusive commercialization rights in mainland China…
-
Pfizer Considers Sale of Hospital Unit Amid Pressure from Starboard Value
•
Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital, in response to pressure from activist investor Starboard Value, as per information from Reuters. The move is part of the US pharmaceutical giant’s strategy to divest non-core assets and focus on its core businesses. Background…
-
FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo
•
US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing revenues of USD 46.3 million for the quarter, a 15% year-on-year (YOY) increase. The net loss narrowed significantly to USD 17.1 million, compared to USD 63.6 million during the same period last year. As of…
-
AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials
•
UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the Q3 2024 period, showing a robust 21% year-on-year (YOY) increase in total revenues to USD 13.565 billion at constant exchange rates. Product sales also saw a significant 20% growth to USD 12.947 billion. Business Unit…
-
BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its Q3 2024 financial results, achieving total operating revenue of USD 1.002 billion, marking a 28% year-on-year (YOY) increase. Product revenue within this total saw a substantial 67% YOY rise to USD 993 million. For the…
-
Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals
•
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6% year-on-year (YOY) growth in constant currency terms to EUR 9.968 billion (USD 10.59 billion) in global group sales. This growth was driven by strong performances in the Pharmaceuticals and Consumer Healthcare segments, offsetting a decline…
